Highlighted Therapeutic Expertise

As a global full-service CRO, Medpace central laboratory conducts Phase I – IV trials for multiple therapeutic areas around the world.

Oncology

Along with our experienced CRO and strategic anatomical pathology lab partners, Medpace’s central lab has broad experience in managing oncology (e.g. Hematological, Immuno-Therapy, and Solid Tumors) clinical trials. Medpace has been proactive in implementing testing capabilities that match the spectrum of oncology clinical development approaches needed to support pharmaceutical industry partners.

Medpace’s central lab has a team of PhD directors overseeing the expansion of Medpace’s oncology test menu with newly validated biomarkers in support of our clients’ oncology programs. Medpace’s oncology capabilities include flow cytometry, molecular/genomics (e.g. PCR, NGS and Sanger Sequencing), as well as many oncology biomarkers.

Central Lab Services

Medpace’s strategic partnership provides our clients with access to board-certified pathologists and state of the art histology services.

Lipid Disorders, Cardiovascular, and Metabolic Diseases

Medpace’s central laboratories have unparalleled experience and expertise in the development of lipid and cardiovascular modifying therapies. Key staff involves doctors, managers, and technologists with considerable expertise in the area of central laboratory operations for the pharmaceutical industry and federally funded programs, from discovery and proof of concept through large, long term global lipid and cardiovascular trials.

• Since 1985, this core group has been part of central laboratory operations for virtually every successful New Drug Application (NDA) involving lipid modifying therapies including, but not limited to, all “statins”, apo B antisense, and omega-3 agents.
• Recently Medpace has provided efficacy analysis for two Proprotein convertase subtilisin/kexin type 9 (PCSK9) mAb inhibitors that supported acceptance of the FDA biologics license application (BLA), European & Global filing, and subsequent approvals by the FDA and EMEA.
• Medpace has been the global central laboratory for Phase I – IV trials involving numerous lipid altering mechanisms including Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition involving monoclonal antibodies, RNA interference, and fusion proteins, cholesterylester transfer protein (CETP)  inhibition, Diacylglycerol Transferase (DGAT-1) inhibition, peroxisome proliferator-activated receptor (PPAR)  agonism, omega-3 fatty acids, niacin analogs, and modifications of other biomarkers known to affect lipid metabolism such as Apo CIII and ANGPTL3 (angiopoietin-like 3).

Central Lab Services

Key Instrumentation

All four central lab locations globally participate in and are certified in the CDC (Center for Disease Control and Prevention) Lipid Standardization Part III Program for total cholesterol, triglyceride, High-Density Lipoprotein Cholesterol (HDL-C), and Low-Density Lipoprotein Cholesterol (LDL-C). Many lipid trials require LDL-C by the gold standard reference method, preparative ultracentrifugation (PUC), which is performed in high volume at Medpace with over 2,000 analyses monthly. Determination of efficacy, and safety, necessitates an accurate evaluation of drug effect, without the confounder of inaccurate data due to a less than optimal laboratory methodology. Medpace labs will get involved early in a drug development program, to aid in the determination of the best method for a clinical trial.

Infectious Diseases

Infectious disease studies have grown in complexity with traditional microbiology methods increasingly supplemented with new molecular techniques, providing rapid and accurate data, facilitating improved understanding of disease mechanism and enhance clinical outcomes.  Medpace’s central laboratories’ in house capabilities coupled with strategic laboratory partnerships with top labs in microbiology and virology provide the specific testing required for each study.  This approach streamlines timelines, simplifies requirements for sites, and provides a centralized model for communication.

Medpace Advantages for Infectious Diseases Studies

• Access to top research scientists who are therapeutically focused on infectious disease, deliver regulatory-quality reports and meet the tight timelines demanded in ID trials
• With Medpace central labs coordinating the shipping between sites and labs around the world, logistics are greatly simplified, resulting in higher efficiency
• Specialty labs integrate seamlessly with Medpace’s full-service approach to clinical trial management

Central Lab Services